Introduction
In the past few decades, attention has been paid to the possibility that some antihypertensive drugs exert their cardiovascular protective effects not only by the blood pressure reduction but also through specific blood pressure-independent organ protective properties. This article addresses the issue of the blood pressure-independent benefits of antihypertensive drugs, focusing on ACE inhibitors and angiotensin II receptor blockers, that is, on two drug classes for which the pressure-independent protective properties (also known as 'ancillary properties') have been most frequently claimed. The point will be made that, for lack of affordable information on the actual blood pressure effect as well as for a number of other reasons, these benefits cannot be easily proven, beyond any doubt, even in the context of controlled trials.
Clinic versus ambulatory blood pressure control
A prerequisite to the hypothesis that an antihypertensive drug has blood pressure-independent protective effects is that its administration reduces cardiovascular morbidity and mortality more than another drug that guarantees an identical blood pressure reduction. The classic tool for assessing a blood pressure reduction in trials has always been clinic or office blood pressure measurements. However, it is now well established that the effects of antihypertensive drug treatment on out-of-office blood pressure values may be quite different. 1 The European Lacidipine Study on Atherosclerosis (ELSA) examined the effects of a 4-year treatment with lacidipine or atenolol in 2334 patients with hypertension, in whom blood pressure was measured at yearly intervals both by clinic and 24-h monitoring. 2, 3 In the pre-randomization state there were marked differences between these two blood pressure values. Furthermore, and more importantly, the effect of treatment on clinic blood pressure was not accurately reflected by the effect of treatment on ambulatory blood pressure, the two sets of values showing a significant but very weak relationship throughout the study. For example, the correlation coefficient values at the fourth year of treatment were 0.28 and 0.16 for systolic and diastolic blood pressure, respectively.
3 Similar results have been obtained in other trials such as the Hypertension Optimal Treatment (HOT), 4 the International Nifedipine GITS study Intervention as a Goal in Hypertension Treatment (INSIGHT) 5 and the Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS). 6 Blood pressure control and cardiovascular outcome
The data commented above lead to the conclusion that two different types of antihypertensive therapeutic strategies may have a similar lowering effect on clinic blood pressure, without necessarily lowering also 24-h blood pressure to a similar degree. This is again exemplified by the ELSA trial in which atenolol and lacidipine lowered clinic blood pressure to a similar degree, whereas the former drug had a greater antihypertensive effect on ambulatory blood pressure than the latter. 3 This must be complemented with the consideration that, at least in individuals with a high cardiovascular risk, even small differences in blood pressure could mean large differences in cardiovascular outcome. For clinic blood pressure this has been shown in a number of trials, 7, 8 but the important point is that the relationship between cardiovascular outcome and blood pressure is even steeper for out-of-office values.
The Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study monitored cardiovascular outcomes in relation to clinic blood pressure, home blood pressure and 24-h ambulatory blood pressure in more than 2000 subjects representative of the general population of Monza, a town in the outskirt of Milan, Italy. 9 A total of 186 events, including 56 deaths, were recorded over a 131-month follow-up period. All these blood pressure measures (including daytime and night time blood pressure) were significant predictors of cardiovascular death based on the goodness of fit in a Cox proportional hazards model. However, a 10-mm Hg increase in mean systolic (and, to a lesser extent, diastolic) ambulatory blood pressure raised the risk of cardiovascular death in a progressively greater manner from office to home, 24-h and night time values. 9 The PAMELA study also showed that information provided by clinic blood pressure, home blood pressure and ambulatory blood pressure measurements are complementary in terms of risk assessment. This is illustrated in Figure 1 , which shows the risk associated with an increase in clinic blood pressure, home blood pressure and/or 24-h ambulatory blood pressure above their respective normality values. 10, 11 It is clear that each blood pressure measure provides additive information on risk, although the additive power is greater when a dichotomized, rather than a continuous, categorization was used.
Altogether these data underline the difficulty of establishing equivalent blood pressure control when two antihypertensive drugs or treatment strategies are compared and emphasize the need for obtaining demonstration that the antihypertensive effects are similar also on 24-h average and perhaps home blood pressure. The argument can additively be advance that information on the blood pressure effects of treatment may have to be even more complete because (1) several blood pressure phenomena within the 24-h period, for example, blood pressure variability, blood pressure fall at night and early morning blood pressure surge, have all been shown to be independently predictive of cardiovascular events 12, 13 and (2) the effects of antihypertensive drugs on peripheral artery blood pressure (the one which is measured in clinical trials) may not correspond to the effects on central blood pressure, which is the blood pressure seen by the vital organs. 14, 15 Additional problems with demonstrating blood pressure-independent effect of treatment in clinical trials
In addition to the difficulty of establishing equivalent blood pressure control, many other factors contribute to make the ability of trials to detect non-blood pressure-dependent drug effects difficult. One major trial limitation is the large patient dropout (up to 30-40%) from randomized treatment, as well as the frequent occurrence of unplanned crossover between treatment groups. 16 In the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT), an unplanned crossover occurred in more than 20% of patients. 17 As the analysis of trial data is performed by 'intention-to-treat', this reduces the actual treatment differences between groups, and consequently the chance of outcome differences. Other limitations include the short-term duration of trials (usually around 3-5 years) and the inclusion of nonresponders, that is, patients in whom the drug has no blood pressure effect. As little benefit can be expected in these non-responders, this reduces the degree of benefit that may be induced in responders.
Evidence for cardiovascular protection induced by drugs acting on the renin-angiotensin system Growing evidence indicates that antihypertensive drugs may exert favourable effects on cardiovascular risk additional to the ones triggered by the blood pressure reduction (Figure 2 ). The evidence is particularly strong for drugs acting against the renin-angiotensin system. In the Losartan Intervention For Endpoint (LIFE) study, for example, 9193 participants aged 55-80 years with essential hypertension were randomized to treatment with losartan or atenolol for at least 4 years. 18 The reductions in blood pressure observed were comparable between treatments, clinic blood pressure falling by 30.2/ 16.6 mm Hg and by 29.1/16.8 mm Hg in the losartan and atenolol groups, respectively. In a small subgroup of patients, the two treatment arms also showed a similar reduction in ambulatory blood pressure. 19 However, the primary composite end point (death, myocardial infarction or stroke) occurred in 508 losartan-treated patient and in 588 atenolol-treated patients, with a 24% reduction of the incidence of stroke in the former group. Greater reductions in the incidence of cardiovascular events for an apparently similar reduction in blood pressure have been reported in other trials using eprosartan 20 and valsartan, 21 although no out-ofoffice blood pressure values were available.
The background for the favourable effects of drugs acting on the renin-angiotensin system is represented by the fact that angiotensin II is directly and indirectly involved in a variety of pathological processes that may favour the development as well as the progression of cardiovascular disease. Angiotensin II may indeed participate at the thrombotic process by favouring the release of the plasminogen activator-inhibitor 1 and interact directly to favour platelet aggregation on the AT1-type receptors expressed on platelet surface. 22 In addition, several studies have described potent proinflammatory properties of angiotensin II, which appear to be mediated by the enhancement of the reactive oxygen species generation, the increase expression of cell adhesion molecules as well as the stimulation of release of cytochines and chemoattractants such as interleukin. 23 Drugs acting on the renin-angiotensin system can directly modify risk factors including inflammatory markers, prevent organ damage, and may play a role in the prevention of disease, such as diabetes, end-stage renal disease, metabolic syndrome and possibly heart failure, this being particularly the case for renin-angiotensin blockers (Table 1) . Pharmacological blockade of the reninangiotensin system may indeed cause a reduction in platelet aggregation combined to an increase in the endogenous fibrinolitic process, that is, effects of key importance for counteracting the pathogenesis of atherosclerosis and thrombosis. 24 In addition, drugs interfering with the renin-angiotensin system have been shown to improve microcirculation, reducing the media-to-lumen ratio and thus reversing the structural alterations of the small resistance arteries, which participate at the development as well as at the progression of the hypertensiondependent increased thickness of the small-size as well as medium-size and large arteries. 24 Other mechanisms throughout which ACE inhibitors and angiotensin II receptor blockers exert their favourable cardioprotective effects should be mentioned. These include the ability of the drugs to improve endothelium-dependent vasodilation and to increase nitric oxide bioavailability stimulating endothelial production and release of this substance throughout several pathways. 24 In addition, reninangiotensin blockade interferes with the expression of platelet-derived growth factor-b, monocyte chemoattractant protein 1 and vascular cell adhesion molecule 1. 26 It also reduces angiotensin 1 receptordependent activation of the oxidant enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, increasing the activity of the vascular antioxidant enzyme extracellular superoxide dismutase. 27 Other mechanisms include the antiproliferative effects of the renin-angiotensin blockade on smooth muscle cells, which concur with the other above-mentioned mechanisms at the antiatherogenic properties of both ACE inhibitors and angiotensin II receptor blockers. 24 Finally, some blood pressure-independent effects of these classes of drugs may be related to the favourable interaction that renin-angiotensin blockade has with the sympathetic nervous system. 28 Indeed, evidence has been provided that chronic blockade of the system by an ACE inhibitor or an angiotensin II receptor blocker may reduce the sympathetic overactivity characterizing a variety of diseases, such as hypertension, congestive heart failure, renal failure and obesity. 28 
Angiotensin II receptor blockers versus ACE inhibitors on hard end points
To date, angiotensin II receptor blockers and ACE inhibitors are largely used for the treatment of hypertension, coronary heart and heart failure. Furthermore, their range of clinical use has recently been expanded as a result of proven protective effects against renal deterioration in diabetic nephropathy and their favourable metabolic effects, including the delay or prevention of diabetes 29 and possibly hypertension. 30 These two classes of drugs do affect renin-angiotensin cascade at different levels, which lead to different patterns of renin and angiotensin effect that may potentially translate in different clinical consequences. However, whether or not the two classes differ clinically is still open to debate. In a recent meta-analysis, comparison of an ACE inhibitor and an angiotensin II receptor blockers in conditions of impaired cardiac function such as heart failure and postmyocardial infarction has not shown significant differences. 31 No difference in clinical outcomes has also been reported in other meta-analyses, 32, 33 including the one that taking into account 25 trials involving a total of 68 711 patients at risk for coronary events, which showed that the odds ratio for a myocardial infarction associated with an angiotensin II receptor blockers was 1.03. 32 Nevertheless, another metaanalysis has reported that angiotensin II receptor blockers, which are beneficial on stroke and heart failure outcomes, may be less effective with regard to myocardial infarction. 25 Furthermore, metaregression analyses have suggested that, at a projected absence of any blood pressure reduction by treatment, ACE inhibitors retained a substantial ability to reduce the incidence of heart failure and coronary heart disease, whereas neither ACE inhibitors and angiotensin II receptor blockers retained the ability to reduce stroke, the protection against which appeared thus to be strictly blood pressuredependent. [34] [35] [36] [37] Comparison between the cardioprotective effects of an ACE inhibitor and an angiotensin II receptor antagonist-based treatment has been recently evaluated in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), 38 which, together with the Telmisartan Randomised AssessmeNT Study in ACE INtolerant subjects with cardiovascular Disease (TRASCEND), 39 represents the largest trial ever performed in the field of cardiovascular protection. The results of ONTARGET trial unequivocally show that telmisartan has the same efficacy, in terms of cardiovascular protection (reduction in myocardial infarction, stroke and hospitalization for congestive heart failure ( Figure 3 ), of ramipril, although guaranteeing a better tolerability profile (Figure 4 ). This is of major clinical relevance, given the evidence that patient's compliance to antihypertensive drug treatment closely depends on tolerability and thus on the occurrence of side effects. Renin
Angiotensin II receptor blockers versus ACE inhibitors on intermediate end points
Taken together the results of the previously mentioned recent clinical trials and meta-analyses suggest that the differences in the incidence of cardiovascular morbidity and mortality between ACE inhibitors and angiotensin II receptor blockers are, if present, small. This does not allow to provide any documented evidence on the superiority of one class of drugs over the other on these specific end points. Some differences, however, may exist, as far as intermediate end points are concerned. Three of them will be examined in this review, that is, the effects of the two drug classes on (1) left ventricular hypertrophy an myocardial fibrosis, (2) vascular hypertrophy and structural alterations of the microcirculation and (3) cerebral circulation.
As far as left ventricular hypertrophy is concerned, although more than 60 echocardiographic studies have evaluated the effects of angiotensin II receptor blockers on left ventricular hypertrophy in hypertension, no more than 10% of them fulfilled rigorous methodological criteria. Overall, these studies involved about 1900 patients, randomized to 12 treatment arms using different drugs, such as losartan, irbesartan, candesartan, amlodipine, enalapril and atenolol. The left ventricular REGression with the Angiotensin Antagonist Losartan (RE-GAAL) trial was a 36-week multicentre study comparing the effect of losartan and atenolol in 225 patients with left ventricular mass greater than 120 and 105 g m À2 in men and women, respectively. 41 Losartan-based regimen significantly reduced left ventricular mass index from baseline, whereas atenolol had no significant effect. The Candesartan Assessment in the Treatment of Cardiac hypertrophy (CATCH), 42 an European multicentre study designed to compare the effects of candesartan and enalapril in 239 hypertensive patients with echocardiographic evidence of an increased left ventricular mass, showed that candesartan and enalapril reduced left ventricular mass to a similar extent. Some differences between the two drug regimens were detectable, however. This is because in the candesartan-treated group, the proportion of patients achieving full normalization of left ventricular mass index or changing from the concentric to the eccentric geometry of the left ventricle was higher. In the CardioVascular Irbesartan Project, 240 patients with essential hypertension were treated with irbersartan and atenolol for 18 months. A significant reduction in left ventricular mass index was observed only in subjects within the highest quartile of baseline left ventricular mass in the irbesartan but not in the atenolol-treated arm. 40 Another study 43 evaluated the effect of valsartan and amlodipine on left ventricular mass index and inflammatory markers (reactive oxygen species, C-reactive protein) in 104 patients with hypertension and cardiac hypertrophy over a period of 8 months. Despite similar blood pressure lowering effects, significant differences on left ventricular mass index were found between valsartan and amlodipine treatment as well as on inflammatory markers. Finally, the echocardiographic LIFE substudy was designed to test the ability of losartan to reduce left ventricular mass more than atenolol over a period of 5 years. 44 Blinded readings of echocardiograms in 457 losartan-treated and 459 atenololtreated participants were used in an intention-totreat analysis. Losartan-based therapy induced a greater reduction in left ventricular mass index from baseline to the last available echocardiogram than atenolol after adjustment for baseline echocardiographic and blood pressure values.
Two further surrogate end points for the assessment of the cardiovascular effects of antihypertensive drugs should be mentioned. The first one is represented by myocardial fibrosis, based on the consideration that angiotensin II has profibrotic effects on the myocardial tissue, which may affect also the fibrous perivascular and interstitial tissue. 45 Although no study has directly compared the effects of ACE inhibitors versus angiotensin II receptor blockers on this specific end point, evidence collected in the already mentioned REGAAL study has shown the ability of losartan, but not of atenolol, to decrease myocardial collagen content. 41 The second surrogate end point of interest for comparing the effects of different antihypertensive drug regimen is represented by the vascular structural changes occurring in the microcirculation in the presence of elevated blood pressure, such as the increase in the tunica media to internal lumen of the vessel ratio. 46 Evidence has been provided that longterm treatment with ACE inhibitors and angiotensin II receptor blockers may reverse and even normalize the structural alterations in the subcutaneous resistance arteries. 47, 48 However, whether differences exist between the two drug classes acting on the renin-angiotensin system is still unknown. The only available study performed in diabetic hypertensive patients indicates that candesartan and enalapril were equally capable to reduce vascular structural alterations. 49 Candesartan, however, was more effective in reducing collagen content in the vascular wall, a finding that underscore the antifibrotic properties of angiotensin II receptor blockade. 49 Finally, further data related to the vis-à-vis comparison between an ACE inhibitor and an angiotensin II receptor antagonist have been implemented by the results of another trial of recent publication, the Prevention Regimen for Effectively Avoiding Secondary Stroke (PROFESS), 50 that is, the largest secondary stroke prevention trial ever done. In PROFESS, more than 20 000 patients have been randomized either to telmisartan or placebo, both added to conventional treatment, and followed for more than 3 years. Although the results have shown a similar protection of the two drug regimens, they are open to some criticisms, given the evidence that in telmisartan-treated group there was a large blood pressure reduction greater for magnitude than the one seen in the so-called placebo group. However, a much closer analysis of the PROFESS trial data indicates that the benefits of an angiotensin II receptor blocker on recurrent stroke are present but they begin to appear after 6 months of treatment. These results are supported by recent meta-analysis on this clinical end point. 51, 52 The demonstration of a special cerebrovascular protective effect of angiotensin II receptor blockers will then require the physician to make a 'judgement call' when deciding on which treatment to adopt. For example, angiotensin II receptor blockers may be the preferred option whenever the risk of stroke is felt to predominate, which is usually the case for a patient with a history of stroke or transient ischaemic attack, chronic or paroxysmal atrial fibrillation or an Asian ethnicity, and this may possibly be the case in patients with left ventricular hypertrophy and in those with coexisting dilatation of the left atrium.
Conclusions
Clinical trials have shown that for similar reductions in office blood pressure, antihypertensive drugs may have different effects on cardiovascular morbid and fatal events as well as on variables such as organ damage of prognostic significance for future outcomes. This may be particularly the case for angiotensin II receptor antagonists. Whether in trials differences in such effects are due to treatmentrelated variations in other (but unmeasured) blood pressure parameters or are truly blood pressureindependent effects is an area for further research.
